Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Ryerson University

$25,000.00

A glass-based carrier for bone morphogenetic proteins.

EF 2013-14

Résumé
Sustained release carriers for Bone Morphogenetic / Morphogenic Proteins (BMPs) are conventionally polymeric based, where the BMP is released as the polymer degrades. Loading of BMP into these polymers requires the use of organic solvents which can denature the BMP. The polymers themselves also have possible immunological issues and can cause an inflammatory response from surrounding tissue which impacts performance. Glass polyalkenoate cements (GPCs) are formed by the reaction of an ion leachable alumino-silicate glass with an aqueous solution of polyalkenoic acid (PAA), with water used as the reaction medium. An acid-base reaction occurs, whereby the PAA attacks and degrades the glass structure, releasing metal cations which are then chelated by the carboxylate groups and serve to crosslink the polyacid chains. A novel injectable 3D scaffold, based on GPC chemistry, may provide suitable strength and offer controllable retention and release of BMPs, while providing the versatility of injectability. It may also be possible to formulate the GPC carrier out of a novel glass phase that, in and of itself, offers a further therapeutic effect due to ion release from the glass as it sets to form a cement. In 2010, the bone repair and regenerative products segment of the orthobiologics market was estimated to be a US$3.3 billion market, with projected growth rates of 4%. Sales of BMP containing bioimplants reached almost $700 million in 2012. The development of a patentable, injectable carrier that delivers BMP more efficiently and can be used in load bearing applications in the skeleton may not only increase the clinical applicability of BMPs but may also minimise the amount required per treatment. This unique approach to designing a wholly new BMP carrier may result in new revenue and employment in the healthcare field, a discipline that currently offers employment to over 35,000 Canadian workers.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
449981-2013
Name nom
Towler, Mark
Department département
Mechanical and Industrial Engineering
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
A glass-based carrier for bone morphogenetic proteins.
Keyword
NSERC
Application summary
Sustained release carriers for Bone Morphogenetic / Morphogenic Proteins (BMPs) are conventionally polymeric based, where the BMP is released as the polymer degrades. Loading of BMP into these polymers requires the use of organic solvents which can denature the BMP. The polymers themselves also have possible immunological issues and can cause an inflammatory response from surrounding tissue which impacts performance. Glass polyalkenoate cements (GPCs) are formed by the reaction of an ion leachable alumino-silicate glass with an aqueous solution of polyalkenoic acid (PAA), with water used as the reaction medium. An acid-base reaction occurs, whereby the PAA attacks and degrades the glass structure, releasing metal cations which are then chelated by the carboxylate groups and serve to crosslink the polyacid chains. A novel injectable 3D scaffold, based on GPC chemistry, may provide suitable strength and offer controllable retention and release of BMPs, while providing the versatility of injectability. It may also be possible to formulate the GPC carrier out of a novel glass phase that, in and of itself, offers a further therapeutic effect due to ion release from the glass as it sets to form a cement. In 2010, the bone repair and regenerative products segment of the orthobiologics market was estimated to be a US$3.3 billion market, with projected growth rates of 4%. Sales of BMP containing bioimplants reached almost $700 million in 2012. The development of a patentable, injectable carrier that delivers BMP more efficiently and can be used in load bearing applications in the skeleton may not only increase the clinical applicability of BMPs but may also minimise the amount required per treatment. This unique approach to designing a wholly new BMP carrier may result in new revenue and employment in the healthcare field, a discipline that currently offers employment to over 35,000 Canadian workers.